Etrolizumab

Etrolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from rat)
Target	β7 subunit of α4β7 and αEβ7 integrin heterodimers
Identifiers
CAS Number	1044758-60-2^N
ATC code	none
IUPHAR/BPS	8407
ChemSpider	none
UNII	I2A72G2V3J^Y
Chemical data
Formula	C₆₃₉₆H₉₈₇₄N₁₇₀₂O₂₀₁₀S₄₂
Molar mass	144.1 kg/mol
^NY (what is this?) (verify)

Etrolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory bowel disease.^[1]

Etrolizumab was developed by Genentech.

Etrolizumab has been shown to induce remission in up to 21% Ulcerative Colitis in a set of clinical trials conducted between 2011 and 2012.^[2]

References

↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab" (PDF). American Medical Association.
↑ Clark, Brian. "Etrolizumab is a Promising Drug to Cause Remission in Moderate to Severe Ulcerative Colitis". Human Data Project. Human Data Project. Retrieved 28 March 2016.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Durvalumab Eldelumab Fresolimumab Golimumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab Ulocuplumab Varlilumab immune activation: Ipilimumab Nivolumab Pembrolizumab Tremelimumab Urelumab other: Bertilimumab Zanolimumab

Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab

Humanized ("-lizu-")	immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Itolizumab Lampalizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab TGN1412^§ non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Monday, March 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.